The traditional prostate cancer diagnostic indicator, blood PSA, has faced criticism in recent years due to its lack of specificity, false positives, and potential for overdiagnosis in benign prostate disorders (5), As PSA levels do not directly correlate with prostate cancer staging, there is a need for biomarkers with higher specificity and sensitivity in clinical management. The gene discussed is KLK3; the disease is Familial prostate cancer.